Table 1.
Baseline demographic data.
| All patients N = 124 | Healing in 6-M Group N = 61 | Non-Healing in 6-M Group N = 63 | P value | |
| Age (yr) | 73.0 (63–80) | 71.0 (58–84) | 73.0 (67–78) | .540 |
| Gender-Male, N (%) | 75 (60.5%) | 42 (68.9%) | 33 (52.4%) | .091 |
| Body mass index, kg/m2 | 22.9 (19.8–26.4) | 24.4 (20.1–26.9) | 21.9 (19.4–26.1) | .180 |
| Current smoker, N (%) | 9 (7.3%) | 6 (9.8%) | 3 (4.8%) | .493 |
| Hypertension, N (%) | 95 (76.6%) | 45 (73.8%) | 50 (79.4%) | .601 |
| Diabetes mellitus, N (%) | 87 (70.2%) | 40 (65.6%) | 47 (74.6%) | .367 |
| Hyperlipidemia, N (%) | 32 (25.8%) | 11 (18%) | 21 (33.3%) | .082 |
| Chronic lung disease, N (%) | 13 (10.5%) | 9 (14.8%) | 4 (6.3%) | .217 |
| Congestive heart failure, N (%) | 44 (35.5%) | 20 (32.8%) | 24 (38.1%) | .667 |
| Coronary artery disease, N (%) | 44 (35.5%) | 19 (31.1%) | 25 (39.7%) | .421 |
| Old myocardial infarction, N (%) | 1 (0.8%) | 0 (0.0%) | 1 (1.6%) | 1.000 |
| History of CABG, N (%) | 6 (4.8%) | 2 (3.3%) | 4 (6.3%) | .680 |
| Previous PCI, N (%) | 31 (25%) | 14 (23%) | 17 (27.0%) | .756 |
| History of peripheral artery disease, N (%) | 40 (32.3%) | 16 (26.2%) | 24 (38.1%) | .222 |
| Previous lower limb bypass, N (%) | 5 (4.0%) | 2 (3.3%) | 3 (4.8%) | 1.000 |
| Prior stroke or TIA, N (%) | 17 (13.7%) | 6 (9.9%) | 11 (17.5%) | .331 |
| Current dialysis, N (%) | 43 (34.7%) | 17 (27.9%) | 26 (41.3%) | .168 |
| Chronic kidney disease∗, N (%) | 69 (55.6%) | 28 (45.9%) | 41 (65.1%) | .049 |
| Atrial fibrillation, N (%) | 18 (14.5%) | 6 (9.8%) | 12 (19.0%) | .230 |
| Collagen vascular disease, N (%) | 10 (8.1%) | 4 (6.6%) | 6 (9.5%) | .744 |
| Creatinine (mg/dL) | 1.4 (0.9–5) | 1.2 (0.8–4.5) | 1.8 (1–5.3) | .229 |
| Estimated GFR (ml/min) | 44.0 (10.4–84) | 63.1 (10.2–88.9) | 35.6 (10.5–74.9) | .185 |
| HbA1C (mg/dL) | 6.9 (6.1–8.7) | 7.0 (6.2–9.2) | 6.9 (6–8.4) | .333 |
| LDL cholesterol, mg/dL | 75.5 (56–101.8) | 77.0 (59–105) | 74.0 (54–101) | .612 |
| Hemoglobin, g/dL | 10.1 (8.6–11.7) | 10.8 (8.9–12.9) | 9.7 (8.5–10.7) | .004 |
| ABI | 0.8 (0.6–1) | 0.8 (0.6–1) | 0.8 (0.6–1) | .664 |
| Rutherford classification, N (%) | <.001 | |||
| Category 5 | 54 (43.5%) | 37 (60.7%) | 17 (27%) | |
| Category 6 | 70 (56.5%) | 24 (39.3%) | 46 (73.0%) | |
| University of Texas classification, N (%) | .057 | |||
| Grade 0 | 11 (8.9%) | 8 (13.1%) | 3 (4.8%) | |
| Grade 1 | 43 (34.7%) | 25 (41%) | 18 (28.6%) | |
| Grade 2 | 29 (23.4%) | 14 (23%) | 15 (23.8%) | |
| Grade 3 | 41 (33.1%) | 14 (23%) | 27 (42.9%) | |
| Infection, N (%) | 66 (53.2%) | 30 (49.2%) | 36 (57.1%) | .479 |
| Medications,N (%) | ||||
| Aspirin | 102 (82.3%) | 52 (85.2%) | 50 (79.4%) | .534 |
| Clopidogrel | 110 (88.7%) | 52 (85.2%) | 58 (92.1%) | .360 |
| Cilostazol | 80 (64.5%) | 43 (70.5%) | 37 (58.7%) | .238 |
| Pentoxifylline | 7 (5.6%) | 4 (6.6%) | 3 (4.8%) | .715 |
| Warfarin or NOAC | 11 (8.9%) | 5 (8.2%) | 6 (9.5%) | 1.000 |
| ACEI/ARB | 54 (43.5%) | 24 (39.3%) | 30 (47.6%) | .454 |
| Statin | 74 (59.7%) | 36 (59.0%) | 38 (60.3%) | 1.000 |
| Beta blocker | 38 (30.6%) | 14 (23%) | 24 (38.1%) | .102 |
| Calcium channel blocker | 61 (49.2%) | 32 (52.5%) | 29 (46.0%) | .592 |
| Insulin | 32 (25.8%) | 16 (26.2%) | 16 (25.4%) | 1.000 |
| Prostaglandin E1 | 35 (28.2%) | 19 (31.1%) | 16 (25.4%) | .609 |